$DERM
Journey Medical Corp

2022 Q1 Form 10-Q Financial Statement

#000141057822001266 Filed on May 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q4 2021 Q1
Revenue $23.30M $17.52M $10.72M
YoY Change 117.33% -60.66%
Cost Of Revenue $8.203M $9.525M $3.908M
YoY Change 109.9% -34.73%
Gross Profit $15.09M $7.992M $6.811M
YoY Change 121.6% -73.3%
Gross Profit Margin 64.79% 45.62% 63.54%
Selling, General & Admin $14.72M $15.06M $6.226M
YoY Change 136.35% -31.81%
% of Gross Profit 97.5% 188.4% 91.41%
Research & Development $1.266M $1.992M
YoY Change
% of Gross Profit 8.39% 24.92%
Depreciation & Amortization $1.017M $0.00
YoY Change -100.0%
% of Gross Profit 6.74% 0.0%
Operating Expenses $15.98M $17.05M $6.226M
YoY Change 156.68% -22.81%
Operating Profit -$888.0K -$9.057M $585.0K
YoY Change -251.79% -215.36%
Interest Expense $389.0K -$4.096M $221.0K
YoY Change 76.02% 486.82%
% of Operating Profit 37.78%
Other Income/Expense, Net -$386.0K -$263.0K -$221.0K
YoY Change 74.66%
Pretax Income -$1.274M -$13.42M $364.0K
YoY Change -450.0% -287.56%
Income Tax $104.0K $8.335M $96.00K
% Of Pretax Income 26.37%
Net Earnings -$1.378M -$21.75M $268.0K
YoY Change -614.18% -511.72%
Net Earnings / Revenue -5.92% -124.17% 2.5%
Basic Earnings Per Share -$0.08 $0.03
Diluted Earnings Per Share -$0.08 -$1.638M $0.02
COMMON SHARES
Basic Shares Outstanding 17.32M 9.158M
Diluted Shares Outstanding 17.32M 10.90M

Balance Sheet

Concept 2022 Q1 2021 Q4 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $41.33M $49.08M
YoY Change
Cash & Equivalents $41.30M $49.10M $19.00M
Short-Term Investments
Other Short-Term Assets $1.608M $2.438M
YoY Change
Inventory $16.14M $9.862M
Prepaid Expenses
Receivables $31.18M $23.11M
Other Receivables $0.00 $0.00
Total Short-Term Assets $90.26M $84.49M
YoY Change 139.75%
LONG-TERM ASSETS
Property, Plant & Equipment $67.00K $89.00K
YoY Change
Goodwill
YoY Change
Intangibles $30.46M $12.55M
YoY Change -16.48%
Long-Term Investments
YoY Change
Other Assets $118.0K $150.0K
YoY Change 2400.0%
Total Long-Term Assets $30.64M $12.79M
YoY Change -23.24%
TOTAL ASSETS
Total Short-Term Assets $90.26M $84.49M
Total Long-Term Assets $30.64M $12.79M
Total Assets $120.9M $97.28M
YoY Change 87.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $26.96M $22.81M
YoY Change 1140.46%
Accrued Expenses $25.89M $22.73M
YoY Change 5.74%
Deferred Revenue
YoY Change
Short-Term Debt $2.569M $5.322M
YoY Change
Long-Term Debt Due $2.569M $5.322M
YoY Change
Total Short-Term Liabilities $60.97M $51.61M
YoY Change 83.93%
LONG-TERM LIABILITIES
Long-Term Debt $14.78M $3.627M
YoY Change
Other Long-Term Liabilities $8.000K
YoY Change
Total Long-Term Liabilities $14.78M $3.635M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $60.97M $51.61M
Total Long-Term Liabilities $14.78M $3.635M
Total Liabilities $79.46M $55.24M
YoY Change 32.75%
SHAREHOLDERS EQUITY
Retained Earnings -$40.25M -$38.87M
YoY Change -859.26%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $41.44M $42.04M $10.77M
YoY Change
Total Liabilities & Shareholders Equity $120.9M $97.28M
YoY Change 87.42%

Cashflow Statement

Concept 2022 Q1 2021 Q4 2021 Q1
OPERATING ACTIVITIES
Net Income -$1.378M -$21.75M $268.0K
YoY Change -614.18% -511.72%
Depreciation, Depletion And Amortization $1.017M $0.00
YoY Change -100.0%
Cash From Operating Activities $884.0K -$3.206M $1.361M
YoY Change -35.05% -162.47%
INVESTING ACTIVITIES
Capital Expenditures -$20.00M -$1.200M
YoY Change 0.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$20.00M -$1.200M
YoY Change 0.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 11.37M 31.80M 9.391M
YoY Change 21.03% -6629.36%
NET CHANGE
Cash From Operating Activities 884.0K -3.206M 1.361M
Cash From Investing Activities -20.00M -1.200M
Cash From Financing Activities 11.37M 31.80M 9.391M
Net Change In Cash -7.750M 27.39M 10.75M
YoY Change -172.08% 695.12%
FREE CASH FLOW
Cash From Operating Activities $884.0K -$3.206M $1.361M
Capital Expenditures -$20.00M -$1.200M
Free Cash Flow $20.88M -$2.006M
YoY Change -131.68%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
85258
CY2022Q1 dei City Area Code
CityAreaCode
480
CY2021Q4 derm Installment Payments Licenses Gross Non Current
InstallmentPaymentsLicensesGrossNonCurrent
4000000
CY2021Q4 derm Imputed Interest On Non Current License Payment
ImputedInterestOnNonCurrentLicensePayment
373000
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001867066
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2022Q1 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2021Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2022Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11316344
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11318344
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-41063
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
JOURNEY MEDICAL CORPORATION
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-1879539
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
9237 E Via de Ventura Blvd.
CY2022Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 105
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Scottsdale
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
AZ
CY2021Q4 derm Licenses Debt Discount Non Current
LicensesDebtDiscountNonCurrent
373000
CY2022Q1 derm Installment Payments Licenses Net Non Current
InstallmentPaymentsLicensesNetNonCurrent
3716000
CY2021Q4 derm Installment Payments Licenses Net Non Current
InstallmentPaymentsLicensesNetNonCurrent
3627000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
773000
CY2021Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
1353000
CY2022Q1 derm Installment Payments Licenses Gross Non Current
InstallmentPaymentsLicensesGrossNonCurrent
4000000
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
434-6670
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2022Q1 dei Trading Symbol
TradingSymbol
DERM
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
41331000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49081000
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
31183000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
23112000
CY2022Q1 us-gaap Inventory Net
InventoryNet
16137000
CY2021Q4 us-gaap Inventory Net
InventoryNet
9862000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1608000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2438000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
90259000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
84493000
CY2022Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
30457000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
12552000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
67000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
89000
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
118000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
150000
CY2022Q1 us-gaap Assets
Assets
120901000
CY2021Q4 us-gaap Assets
Assets
97284000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
26959000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
22812000
CY2022Q1 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
511000
CY2021Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
641000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
25885000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
22733000
CY2022Q1 us-gaap Interest Payable Current
InterestPayableCurrent
66000
CY2022Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
112000
CY2021Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
8000
CY2021Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
812000
CY2022Q1 derm Deferred Cash Payment Discount Current
DeferredCashPaymentDiscountCurrent
206000
CY2022Q1 derm Deferred Cash Payment Current
DeferredCashPaymentCurrent
4794000
CY2022Q1 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
431000
CY2021Q4 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
490000
CY2022Q1 derm Installment Payments Licenses Net Current
InstallmentPaymentsLicensesNetCurrent
2569000
CY2021Q4 derm Installment Payments Licenses Net Current
InstallmentPaymentsLicensesNetCurrent
4510000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
74000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
98000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
60970000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
51614000
CY2022Q1 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
223000
CY2022Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
14777000
CY2022Q1 derm Licenses Debt Discount Non Current
LicensesDebtDiscountNonCurrent
284000
CY2022Q1 us-gaap Liabilities
Liabilities
79463000
CY2021Q4 us-gaap Liabilities
Liabilities
55241000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11318344
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11316344
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
81688000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
80915000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-40252000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-38874000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
41438000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
42043000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
120901000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
97284000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
20796000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10719000
CY2022Q1 us-gaap Other Income
OtherIncome
2500000
CY2022Q1 us-gaap Revenues
Revenues
23296000
CY2021Q1 us-gaap Revenues
Revenues
10719000
CY2022Q1 us-gaap Cost Of Revenue
CostOfRevenue
8203000
CY2021Q1 us-gaap Cost Of Revenue
CostOfRevenue
3908000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1266000
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
14715000
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6226000
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
24184000
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
10134000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-888000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
585000
CY2022Q1 derm Interest Income
InterestIncome
3000
CY2022Q1 us-gaap Interest Expense
InterestExpense
389000
CY2021Q1 us-gaap Interest Expense
InterestExpense
221000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-386000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-221000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1274000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
364000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
104000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
96000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-1378000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
268000
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.02
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17318344
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9158333
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17318344
CY2022Q1 derm Imputed Interest On Non Current License Payment
ImputedInterestOnNonCurrentLicensePayment
284000
CY2022Q1 derm Installment Payments Licenses Net Non Current
InstallmentPaymentsLicensesNetNonCurrent
3716000
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10897096
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
42043000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-1378000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
41438000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
10292000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
22000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7000
CY2021Q1 derm Adjustments To Additional Paid In Capital Extinguishment Of Related Party Payable
AdjustmentsToAdditionalPaidInCapitalExtinguishmentOfRelatedPartyPayable
178000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
268000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
10767000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-1378000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
268000
CY2022Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-76000
CY2021Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
70000
CY2022Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
203000
CY2021Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
221000
CY2022Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
14000
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1017000
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
584000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
22000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
21000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
773000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
22000
CY2021Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
69000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
7995000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-390000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
234000
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
887000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-830000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-472000
CY2022Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-32000
CY2021Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
121000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4732000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
566000
CY2022Q1 derm Increase Decrease In Account Payable Related Party
IncreaseDecreaseInAccountPayableRelatedParty
-130000
CY2021Q1 derm Increase Decrease In Account Payable Related Party
IncreaseDecreaseInAccountPayableRelatedParty
70000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2928000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-395000
CY2022Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
66000
CY2022Q1 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
104000
CY2021Q1 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
26000
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-24000
CY2021Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-15000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
884000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1361000
CY2022Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
20000000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-20000000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
7000
CY2022Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
2000000
CY2021Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1800000
CY2021Q1 us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
12537000
CY2022Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
214000
CY2022Q1 derm License Collaboration And Assignment Agreement Second Installment Payable
LicenseCollaborationAndAssignmentAgreementSecondInstallmentPayable
6285000
CY2022Q1 us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
14763000
CY2022Q1 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
812000
CY2022Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
371000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11366000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9391000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7750000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
10752000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49081000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8246000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
41331000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18998000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
95000
CY2022Q1 derm Deferred Payment For Asset Acquisition
DeferredPaymentForAssetAcquisition
4794000
CY2021Q1 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
135000
CY2021Q1 derm Stock Issuance Costs Incurred During Non Cash Or Partial Non Cash Transaction
StockIssuanceCostsIncurredDuringNonCashOrPartialNonCashTransaction
362000
CY2021Q1 derm Extinguishment Of Related Party Payable Relates To Deferred Tax Assets
ExtinguishmentOfRelatedPartyPayableRelatesToDeferredTaxAssets
109000
CY2022Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 1. ORGANIZATION AND PLAN OF BUSINESS OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Journey Medical Corporation (collectively “Journey” or the “Company”) was formed on July 18, 2014. The Company is a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The Company’s current product portfolio includes nine branded and three authorized generic prescription drugs for dermatological conditions that are marketed in the U.S. The Company acquires rights to future products by licensing or otherwise acquiring an ownership interest in, funding the research and development of, and eventually commercializing, the products through their exclusive field sales organization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of March 31, 2022 and December 31, 2021, the Company was a majority-owned subsidiary of Fortress Biotech, Inc. (“Fortress” or “Parent”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">All dollar amounts discussed in these Notes to Unaudited Condensed Consolidated Financial Statements are in thousands of U.S. dollars, except for per share amounts, and unless otherwise indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At March 31, 2022, the Company had $41.3 million in cash and cash equivalents as compared to $49.1 million at December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 16, 2021, the Company completed an initial public offering (collectively the “Journey IPO” or “IPO”) of its Common Stock, par value $0.0001 (“Common Stock”), which resulted in net proceeds of approximately $30.6 million, after deducting underwriting discounts and other offering costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Prior the Company's IPO, the Company's operations were primarily financed through a working capital note from Fortress, referred to herein as the "Fortress Note," cash generated by operations and cash raised in the Company's private offering of 8% Cumulative Convertible Class A Preferred Stock ("Class A Preferred Stock"). In connection with the closing of the Company's IPO on November 16, 2021, the Company issued 2,231,346 shares of Common Stock resulting from the conversion of all of the Class A Preferred Stock. In addition, the Fortress Note was converted into 1,610,467 shares of Journey Common Stock at the Journey IPO price of $10.00 per share. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company also has access to a $30.0 million East West Bank (“EWB”) borrowing facility, which includes a $10.0 revolving line of credit (with zero outstanding at March 31, 2022), and a $20.0 million term loan with both maturing on January 12, 2026. In January 2022, the Company borrowed $15.0 million against the term loan. Through June 12, 2023, the Company has the option to borrow an additional $5 million under another term loan facility. For the next twelve months from the issuance of these financial statements, the Company will be able to fund its operations through a combination of existing cash and cash equivalents generated from operations and the EWB borrowing facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company regularly evaluates market conditions, its liquidity profile, and various financing alternatives for opportunities to enhance its capital structure. The Company may seek to raise capital through debt or equity financings to expand its product portfolio. If such funding is not available or not available on terms acceptable to the Company, the Company’s current plans for expansion of its product portfolio will be curtailed.</p>
CY2022Q1 derm Product Portfolio Number Of Branded Drugs
ProductPortfolioNumberOfBrandedDrugs
9
CY2022Q1 derm Product Portfolio Number Of Authorized Generic Prescription Drugs
ProductPortfolioNumberOfAuthorizedGenericPrescriptionDrugs
3
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
41300000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49100000
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates made by management include provisions for product returns, coupons, rebates, chargebacks, discounts, allowances and distribution fees paid to certain wholesalers, inventory realization and useful lives of amortizable intangible assets. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</p>
CY2021Q4 derm Installment Payments Licenses Gross Current
InstallmentPaymentsLicensesGrossCurrent
5000000
CY2021Q4 derm Imputed Interest On Current License Payment
ImputedInterestOnCurrentLicensePayment
490000
CY2022Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
8357000
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
5572000
CY2022Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
533000
CY2022Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
7297000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
4290000
CY2022Q1 us-gaap Inventory Gross
InventoryGross
16187000
CY2022Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
50000
CY2022Q1 us-gaap Inventory Net
InventoryNet
16137000
CY2021Q4 us-gaap Inventory Net
InventoryNet
9862000
CY2022Q1 derm Product Portfolio Number Of Branded Drugs
ProductPortfolioNumberOfBrandedDrugs
9
CY2021 derm Renewable Mutual Agreement Term
RenewableMutualAgreementTerm
P10Y
CY2021 derm Termination Written Notice Period To Other Party
TerminationWrittenNoticePeriodToOtherParty
P180D
CY2022Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
37925000
CY2022Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
7468000
CY2022Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
30457000
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
19003000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
6451000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
12552000
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1000000.0
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
584000
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
3050000
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
4067000
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
4068000
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
4067000
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
2855000
CY2022Q1 derm Finite Lived Intangible Assets Amortization Expense After Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
8408000
CY2022Q1 derm Finite Lived Intangible Assets Excluding Assets Not Yet Placed In Service
FiniteLivedIntangibleAssetsExcludingAssetsNotYetPlacedInService
26515000
CY2022Q1 derm Finite Lived Intangible Assets Not Yet Placed In Service
FiniteLivedIntangibleAssetsNotYetPlacedInService
3942000
CY2022Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
30457000
CY2021Q1 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2022Q1 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2021Q1 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2022Q1 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2021Q1 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Net
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet
0
CY2022Q1 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Net
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet
0
CY2022Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
4421000
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2702000
CY2022Q1 derm Accrued Research And Development License Fees Current
AccruedResearchAndDevelopmentLicenseFeesCurrent
160000
CY2021Q4 derm Accrued Research And Development License Fees Current
AccruedResearchAndDevelopmentLicenseFeesCurrent
870000
CY2022Q1 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
3779000
CY2021Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
3833000
CY2022Q1 derm Accrued Coupon And Rebates Current
AccruedCouponAndRebatesCurrent
11627000
CY2021Q4 derm Accrued Coupon And Rebates Current
AccruedCouponAndRebatesCurrent
10603000
CY2022Q1 derm Accrued Reserve For Product Returns Current
AccruedReserveForProductReturnsCurrent
3151000
CY2021Q4 derm Accrued Reserve For Product Returns Current
AccruedReserveForProductReturnsCurrent
3240000
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2747000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1485000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
25885000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
22733000
CY2022Q1 derm Installment Payments Licenses Gross Current
InstallmentPaymentsLicensesGrossCurrent
3000000
CY2022Q1 derm Imputed Interest On Current License Payment
ImputedInterestOnCurrentLicensePayment
431000
CY2022Q1 derm Installment Payments Licenses Net Current
InstallmentPaymentsLicensesNetCurrent
2569000
CY2021Q4 derm Installment Payments Licenses Net Current
InstallmentPaymentsLicensesNetCurrent
4510000
CY2021Q4 derm Installment Payments Licenses Net Non Current
InstallmentPaymentsLicensesNetNonCurrent
3627000
CY2021Q4 derm License Collaboration And Assignment Agreement Second Installment Payable
LicenseCollaborationAndAssignmentAgreementSecondInstallmentPayable
8137000
CY2022Q1 derm Area Of Property Under Lease
AreaOfPropertyUnderLease
3681
CY2020Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P25M
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
100000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
26000
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
23000
CY2022Q1 us-gaap Variable Lease Cost
VariableLeaseCost
1000
CY2021Q1 us-gaap Variable Lease Cost
VariableLeaseCost
1000
CY2022Q1 us-gaap Lease Cost
LeaseCost
27000
CY2021Q1 us-gaap Lease Cost
LeaseCost
24000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
25000
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
18000
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y9M18D
CY2021Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y3M18D
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.040
CY2021Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.040
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
75000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
75000
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
74000
CY2022Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
161000
CY2022Q1 derm Interest Expense Licenses Installments Payments
InterestExpenseLicensesInstallmentsPayments
148000
CY2021Q1 derm Interest Expense Licenses Installments Payments
InterestExpenseLicensesInstallmentsPayments
221000
CY2022Q1 us-gaap Accretion Expense
AccretionExpense
55000
CY2022Q1 derm Interest Expense And Financing Fee
InterestExpenseAndFinancingFee
389000
CY2021Q1 derm Interest Expense And Financing Fee
InterestExpenseAndFinancingFee
221000
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 derm Common Stock Number Of Votes Per Share
CommonStockNumberOfVotesPerShare
1
CY2022Q1 derm Common Stock Voting Rights Ratio
CommonStockVotingRightsRatio
1.1
CY2021Q1 derm Preferred Stock Convertible Percentage Of Discount On Share Price
PreferredStockConvertiblePercentageOfDiscountOnSharePrice
0.075
CY2021Q1 derm Preferred Stock Convertible Number Of Trading Days Prior To Exchange
PreferredStockConvertibleNumberOfTradingDaysPriorToExchange
P10D
CY2022Q1 derm Revenue From Contract With Customer Excluding Assessed Tax.
RevenueFromContractWithCustomerExcludingAssessedTax.
20796000
CY2021Q1 derm Revenue From Contract With Customer Excluding Assessed Tax.
RevenueFromContractWithCustomerExcludingAssessedTax.
10719000
CY2022Q1 us-gaap Other Income
OtherIncome
2500000
CY2022Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
104000
CY2021Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
96000
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0820
CY2021Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.2642
CY2022Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3023652
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
268000
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9158333
CY2021Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1738763
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10897096
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.02

Files In Submission

Name View Source Status
0001410578-22-001266-index-headers.html Edgar Link pending
0001410578-22-001266-index.html Edgar Link pending
0001410578-22-001266.txt Edgar Link pending
0001410578-22-001266-xbrl.zip Edgar Link pending
derm-20220331.xsd Edgar Link pending
derm-20220331x10q.htm Edgar Link pending
derm-20220331x10q_htm.xml Edgar Link completed
derm-20220331xex10d2.htm Edgar Link pending
derm-20220331xex10d3.htm Edgar Link pending
derm-20220331xex10d4.htm Edgar Link pending
derm-20220331xex31d1.htm Edgar Link pending
derm-20220331xex31d2.htm Edgar Link pending
derm-20220331xex32d1.htm Edgar Link pending
derm-20220331xex32d2.htm Edgar Link pending
derm-20220331_cal.xml Edgar Link unprocessable
derm-20220331_def.xml Edgar Link unprocessable
derm-20220331_lab.xml Edgar Link unprocessable
derm-20220331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending